Second, the specific scores are compared as follows:

Chapter I Licensed Pharmacists and Drug Safety

In the first section, the number of 20 15 questions for licensed pharmacists is 5, 20 16 questions are 2, 20 17 questions are 1, and 20 18 questions are 2. The key examination contents are: licensed pharmacist management department, licensed pharmacist examination registration management department, licensed pharmacist registration validity period, licensed pharmacist responsibilities, and conditions for taking the licensed pharmacist examination.

Section 2 Professional Ethics and Service Standards for Licensed Pharmacists: 20 15 ~ 20 17 is 0, and 20 18 is 1. Key content: Professional ethics of licensed pharmacists.

In the third section, there are two questions for 20 15 and 20 16, 20 17 is two, and 20 18 is 1. The key inspection contents are: drug definition, drug quality characteristics, drug risk classification, risk management measures and drug safety planning indicators.

Chapter II Reform of Medical and Health System and Drug Supply Guarantee System

Section 1 Deepening the Reform of Medical and Health System The number of questions for 20 15, 20 16, 20 18 is 0, and the number of questions for 20 17 is 1. The key examination contents are: the basic principles of deepening the reform of medical and health system, the overall goal in 2020, and the contents of establishing the national basic medical and health system.

In the second quarter, the number of problems in drug supply assurance system 20 15 and 20 16 was 0, 20 17 was 4, and 20 18 was 2. The key inspection contents are: reforming and improving the policy of drug production, circulation and use, and the overall requirements of drug supply security system.

In the third section, the number of questions in the national essential drug system for 20 15 years is 4, that for 20 16 years is 3, that for 20 17 years is 2, and that for 20 18 years is 1. The key assessment contents are: the selection principle of essential drugs, the management departments and functions of essential drugs, the varieties to be transferred out of the catalogue, the priority selection of essential drugs and the system of rational use.

Chapter III Drug Supervision and Administration System and Legal System

In the first section, the number of questions given by drug regulatory agency 20 15 is 4, that given by 20 16 is 3, that given by 20 17 is 3, and that given by 20 18 is 0. The main contents are: the responsibilities of health and family planning departments, Ministry of Human Resources and Social Security, industry and information departments and the Ministry of Commerce.

In the second section, the number of questions given by technical support institutions of drug supervision and administration 20 15 to 20 16 is 1, the number of questions given by 20 17 is 3, and the number of questions given by 20 18 is 0. The key contents are: the responsibilities of China Food and Drug Inspection Institute and China Food and Drug Administration Drug Evaluation Center.

In the third section, the number of questions in drug regulatory legislation 20 15 ~ 20 18 is 1, and the number of questions in 20 18 is 4. The main contents of the examination are: legal source, legal system of drug management and legal effectiveness level.

Section IV Drug Supervision and Administration Administrative Legal System 20 15 ~ 20 16 is 2, 20 17 is 3, and 20 18 is 6. The main contents of the review are: administrative licensing principles, drug administrative licensing matters, administrative punishment decisions and procedures, the scope of administrative reconsideration, the definition of administrative reconsideration and the definition of administrative litigation.

Chapter IV Drug Development and Production Management

The first section of drug development and registration management 20 15 is 6, 20 16 is 5, 20 17 is 9, and 20 18 is 6. The key review contents are: the stage and purpose of drug clinical trial, the definition of drug registration application, drug approval number, new drug monitoring period and drug re-evaluation.

In the second section, the number of questions for drug production management 20 15 is 5, 20 16 is 7, 20 17 is 3, and 20 18 is 2. The key contents of the review are: the requirements of raw and auxiliary materials of drugs, licensing matters approved by the drug supervision and administration department, the variety restrictions of entrusted production, the main body of drug recall and the recall time.

Chapter V Administration of Drug Sales and Use

In the first section, the number of questions for drug management 20 15 is 22, 20 16 is 10, 20 17 is 15, and 20 18 is 10. The main contents of the examination are: the change of wholesale and retail licensing matters, personnel qualification requirements, storage and maintenance management of wholesale enterprises, display requirements of retail enterprises, prohibition of purchase and sale of operating enterprises, and internet management.

In the second section, the number of questions in drug use management 20 15 is 9, 20 16 is 10, 20 17 is 15 and 20 18 is 14. The main contents of the inspection include: the responsibilities of the Pharmaceutical Administration and Drug Treatment Committee, the responsibilities of pharmacists, prescription writing rules, prescription limit, prescription suitability review, prescription storage period, prescription destruction approval, definition and characteristics of preparations in medical institutions, preparation licensing departments of medical institutions, preparation distribution records, preparation recovery records and antibacterial drug classification.

In the third section, the number of questions in drug classification management 20 15 is 3, the number of questions in 20 16 is 5, and the number of questions in 20 17 and 20 18 is 6. The key contents of the review are: OTC drug classification basis, OTC drug printing requirements, unique identification color of OTC drugs, 9 types of pharmacies that are not allowed to retail drugs, and the national OTC drug catalogue selection department.

In the fourth section, the number of 20 15 questions in medical security is 3, 20 16 is 2, 20 17 is 1, and 20 18 is 2. The key inspection contents are: drugs that can't be included in the basic medical insurance coverage, whether to pay for drugs, and the adjustment of Class A and B catalogues.

Section 5 The number of problems in reporting, monitoring and management of adverse drug reactions is 4/20 15, 3/20 16, 2/20 17 and 3/20 18. The key contents include: the scope of adverse reaction report, the main body of adverse reaction report, the definition of serious adverse reaction and the new definition of adverse reaction.

Chapter VI Administration of Traditional Chinese Medicine

Section 1 Chinese Medicine and Innovation and Development of Chinese Medicine The number of questions from 20 15 to 20 18 is zero. This section focuses on understanding.

In the second section, 20 15 is 3, 20 16 is 6, 20 17 is 4, and 20 18 is 5. The key contents of the investigation include: the list of national key protected wild medicinal materials, the cultivation and primary processing of Chinese medicinal materials, GAP, the measures for the management of specialized markets of Chinese medicinal materials, and the approval documents of imported medicinal materials.

In the third section, the number of 20 15 questions in the management of Chinese herbal pieces is 3, 20 16 is 1, 20 17 is 2, and 20 18 is 0. The key contents of the inspection are: label standardization of production and operation management, prohibited behavior, and fixed-point production and operation management of toxic Chinese herbal pieces.

Section IV Management of Chinese Patent Medicines and Traditional Chinese Medicine Preparations in Medical Institutions: 20 15 2, 20 16 3, 20 17 3, 20 18 0. The key contents of the review are: the classification of protection grades of traditional Chinese medicine varieties, the requirements of protection years, and the scope of application of the Regulations on the Protection of Traditional Chinese Medicine Varieties.

Chapter VII Administration of Specially Administered Drugs

Section 1 Management of Narcotic Drugs and Psychotropic Substances The number of questions in 20 15 is 7, that in 20 16 is 6, that in 20 17 is 7, and that in 20 18 is 4. The key contents of the inspection are: the catalogue of narcotic drugs and psychotropic drugs, the management of purchasing channels for narcotic drugs and psychotropic drugs, the management of seal cards, the management of special account books for the storage of psychotropic drugs of Category II, and the approval of designated business qualifications.

In the second section, the number of questions for 20 15, 20 16 and 20 18 in the management of toxic drugs for medical use is 1, and the number of questions for 20 17 is 2. The key inspection contents are: prescription dosage and the use and deployment requirements of the payable funds in the prescription.

Section III Management of Pharmaceutical Precursor Chemicals The number of questions in 20 15 is 1, 20 16 is 2, 20 17 is 1, and 20 18 is 0. The key inspection contents are: varieties of precursor chemicals and prohibition of cash or physical transactions.

Section IV Management of Compound Preparations Containing Special Drugs The number of questions in 20 15 is 0, 20 16 is 1, 20 17 is 2, and 20 18 is 4. The key contents are: sales management of compound preparations containing ephedrine and management of compound preparations containing special drugs.

In the fifth section, the number of questions for doping control 20 15 is 1, 20 16 is 2, 20 17 and 20 18 is 4. The key contents of the inspection are: the management of protein assimilation preparations, the varieties of stimulants that can be operated by pharmaceutical retail enterprises, protein assimilation preparations and peptide hormones.

Section VI Vaccine Management 20 15 is 1, 20 16 is 3, 20 17 is 3, and 20 18 is 2. The key contents are: the classification of vaccines, the scope and restrictions of vaccine sales.

Chapter VIII Drug Standards and Drug Quality Supervision and Inspection

In the first section, the number of questions in drug standard management 20 15 is 1, 20 16 is 0, 20 17 and 20 18 is 1. The emphasis is on the classification and effectiveness of drug standards.

Section II Drug Instructions and Label Management 20 15 has 3 questions, 20 16 questions, 20 17 questions and 2,2018 questions. The main contents of the review are: the approving unit of the drug instruction label, the printed or pasted label, the labeling and use requirements of the drug name and registered trademark, the basic content and writing requirements of the drug instruction format, and the drugs with all the names of excipients.

In the third section, the number of questions in drug quality supervision and inspection and drug quality announcement 20 15 is 1, 20 16 is 3, 20 17 is 4, and 20 18 is 3. The key content is: the comparison of four kinds of quality supervision and inspection.

Chapter IX Drug Advertising Management and Consumer Rights Protection

In the first section, the number of 20 15 questions is 2, the number of 20 16 questions is 5, the number of 20 17 questions is 3, and the number of 20 18 questions is 7. The main contents of the review include: drug advertisement examination organ, drugs that are not allowed to publish advertisements, media restrictions on drug advertisements, contents of drug advertisements (scientific requirements), advertising supervision and management organs (punishment organs), and penalties for providing false materials to defraud licenses.

In the second section, the number of questions for the Anti-Unfair Competition Law 20 15 is 2, the number of questions for 20 16 and 20 18 is 1, and the number of questions for 20 17 is 0. The key contents of the review are: the identification of unfair competition behavior.

In the third section, the number of questions for consumer protection 20 15 is 3, 20 16 is 2, 20 17 is 2, and 20 18 is 4. The main contents are: the rights and interests of consumers and the obligations of operators, and the ways to solve disputes.

Chapter X Legal Liability for Drug Safety

Section 1 Legal Responsibility and Characteristics of Drug Safety The number of questions in 20 15 is 4, 20 16 is 2, 20 17 is 0, and 20 18 is 1. The key examination contents are: the types of legal liability for drug safety.

Section 2 Legal Liability for Producing and Selling Fake Drugs and Inferior Drugs The number of questions in 20 15 is 7, 20 16 is 10, 20 17 is 4, and 20 18 is 8. The key contents are: the definition of counterfeit and inferior drugs, the criminal responsibility of counterfeit and inferior drugs, the administrative responsibility of counterfeit and inferior drugs, and the situation of heavier punishment.

Section III Legal Liability for Violating Drug Supervision and Administration Regulations The number of questions in 20 15 is 0, 20 16 is 1, 20 17 is 1, and 20 18 is 4. The main contents of the review are: the legal liability for producing and trading drugs without a license, the legal liability for defrauding licenses or approval documents, the legal liability for forging, altering, buying, selling, renting or lending licenses or approval documents for drugs, and the legal liability for violating drug quality management norms.

Section IV Legal Liability for Violating the Provisions on Specially Administered Drugs The number of questions for 20 15, 20 16 and 20 18 is 1, and the number of questions for 20 17 is 0. The focus is on the legal responsibility of smuggling and illegal trading of ephedrine compound preparations.

Section V Legal Liability for Violating Relevant Provisions of the Law of Traditional Chinese Medicine 20 17 adds a new chapter, and the number of questions in 20 18 is 0.

Chapter II XI Management of Medical Devices, Health Food and Cosmetics

The number of 20 15 questions in the first section of medical device management is 4, 20 16 is 3, 20 17 is 1, and 20 18 is 2. The key assessment contents are: medical device registration, filing classification management, medical device management classification management, medical device definition, medical device classification basis and medical device standard management.

In the second section, the number of questions for health food management 20 15 is 1, 20 16 is 4, 20 17 is 2, and 20 18 is 3. The key contents are: the management of special medical use formula food and infant formula food, the approval number and definition of health food.

In the third section, the number of questions in 20 15 ~ 20 17 is 1, and the number of questions in 20 18 is 0. The key review contents are: classification of cosmetics and approval number of cosmetics.